Synthesis and Antiprotozoal Activity of Azabicyclo-Nonane Pyrimidine Hybrids.

Clemens Hinteregger, Johanna Dolensky, Werner Seebacher, Robert Saf, Pascal Mäser, Marcel Kaiser, Robert Weis

Abstract read

In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Clemens HintereggerPharmaceutical Chemistry, Institute of Pharmaceutical Sciences, University of Graz, Schubertstraße 1, A-8010 Graz, Austria.

Johanna DolenskyPharmaceutical Chemistry, Institute of Pharmaceutical Sciences, University of Graz, Schubertstraße 1, A-8010 Graz, Austria.

Werner SeebacherPharmaceutical Chemistry, Institute of Pharmaceutical Sciences, University of Graz, Schubertstraße 1, A-8010 Graz, Austria.ORCID 0000-0002-5673-0470

Robert SafInstitute for Chemistry and Technology of Materials (ICTM), Graz University of Technology, Stremayrgasse 9, A-8010 Graz, Austria.

Pascal MäserSwiss Tropical and Public Health Institute, Kreuzstraße 2, CH-4123 Allschwil, Switzerland.ORCID 0000-0003-3122-1941

Marcel KaiserSwiss Tropical and Public Health Institute, Kreuzstraße 2, CH-4123 Allschwil, Switzerland.ORCID 0000-0003-1785-7302

Robert WeisPharmaceutical Chemistry, Institute of Pharmaceutical Sciences, University of Graz, Schubertstraße 1, A-8010 Graz, Austria.ORCID 0000-0002-7174-6673

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

2,4-Diaminopyrimidines and (dialkylamino)azabicyclo-nonanes possess activity against protozoan parasites. A series of fused hybrids were synthesized and tested in vitro against pathogens of malaria tropica and sleeping sickness. The activities and selectivities of compounds strongly depended on the substitution pattern of both ring systems as well as on the position of the nitrogen atom in the bicycles. The most promising hybrids of 3-azabicyclo-nonane with 2-aminopyrimidine showed activity against

Indexed as

Antiprotozoal AgentsMalaria, FalciparumAlkanesHumansParasitic Sensitivity TestsPlasmodium falciparumPyrimidinesStructure-Activity RelationshipTrypanosoma brucei rhodesienseAlkanesAntiprotozoal AgentsnonanepyrimidinePyrimidinesazabicyclo-nonaneshybridsPlasmodium falciparumpyrimidineTrypanosoma brucei rhodesiense

Identifiers

PMID36615504

DOI10.3390/molecules28010307

PMCPMC9821907

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.